Share|
  • For 2013: Gross dividend + 2% of € 1.04 per share payable May 5
  • Outlook 2014 confirmed


Brussels (Belgium), 24 April 2014 - 19:30 (CEST) - Today, UCB held its Annual General Meeting (AGM) and Extraordinary General Meeting (EGM). At the Annual General Meeting 142.8 million shares (74.75% of shares outstanding) were represented. During the course of this meeting, Roch Doliveux, Chief Executive Officer UCB and Jean-Christophe Tellier, Chief Executive Officer-Elect and Chairman of the Executive Committee, gave the shareholders of UCB an overview of UCB's strategic growth priorities, the financial year 2013 and the first three months of 2014, and confirmed the financial outlook for 2014. The speech is available on the company's website: http://www.ucb.com/investors/Governance/Shareholders-meeting

The AGM approved for the fiscal year 2013 the payment of a gross dividend of € 1.04 per share (net dividend of € 0.78 per share) compared with € 1.02 per share for 2012 (net € 0.765). The ex-dividend day is 29 April 2014, the dividend (coupon no. 17) will be payable on 5 May 2014.

The AGM appointed Cédric van Rijckevorsel and Jean-Christophe Tellier as Directors, and Kay Davies as Independent Director. For curriculum vitae of the new Board members, please visit UCB website: http://www.ucb.com/investors/Governance/Corporate-governance

Also all other agenda items put to vote were approved by the shareholders represented. For details please visit UCB's website: http://www.ucb.com/investors/Governance/Shareholders-meeting

At the EGM, all agenda items put to vote were approved by the shareholders represented. For details, please see: http://www.ucb.com/investors/Governance/Shareholders-meeting

The Annual Report 2013 of UCB is available on UCB's website: http://www.ucb.com//investors/Financials/Financial-reports/Annual-reports

The interim report on the first three months 2014 has been published today, the financial results for the first half year 2014 will be announced on 30 July 2014 and an interim report for the first nine months of 2014 is due on 24 October 2014.

Next year's AGM will be held on 30 April 2015 in Brussels (Belgium).

For further information

  • Antje Witte, Investor Relations, UCB
    T +32.2.559.9414, antje.witte@ucb.com
  • Alexandra Deschner, Investor Relations, UCB
    T: +32.2.559.9683, alexandra.deschner@ucb.com
  • France Nivelle, Global Communications, UCB
    T +32.2.559.9178, france.nivelle@ucb.com
  • Laurent Schots, Media Relations, UCB
    T +32.2.559.9264, laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 8 700 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements

distributed by